• PDR Search

    Required field
  • Advertisement
  • OxyContin
    (oxycodone hydrochloride)


    Exposes users to risks of addiction, abuse, and misuse, leading to overdose and death; assess each patient's risk prior to prescribing and monitor regularly for development of these behaviors/conditions. Serious, life-threatening, or fatal respiratory depression may occur; monitor during initiation or following a dose increase. Crushing, dissolving, or chewing tab can cause rapid release and absorption of potentially fatal dose; instruct patients to swallow tab whole. Accidental ingestion, especially by children, can result in a fatal overdose. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome; advise pregnant women of the risk and ensure availability of appropriate treatment. Concomitant use of CYP3A4 inhibitors or discontinuation of CYP3A4 inducers can result in oxycodone overdose; monitor patients receiving concomitant CYP3A4 inhibitors/inducers.

    View FDA-Approved Full Prescribing Information for OxyContin


    Opioid analgesic




    Severe Pain (Daily, Around-the-Clock Management)

    1st Opioid Analgesic/Opioid-Intolerant Patients:
    Initial: 10mg q12h
    Titrate: Increase total daily dose by 25-50% every 1-2 days when clinically indicated


    From Other Oral Oxycodone Formulations:
    Administer 1/2 of total daily dose q12h

    From Other Opioids:
    D/C all other around-the-clock opioids when therapy is initiated and initiate dosing using 10mg q12h

    From Transdermal Fentanyl:
    Initiate treatment 18 hrs following removal of patch; 10mg q12h should be initially substituted for each 25mcg/hr fentanyl transdermal patch


    Severe Pain (Daily, Around-the-Clock Management)

    Use in patients ≥11 yrs already receiving and tolerating opioids for at least 5 consecutive days; for the 2 days immediately preceding dosing w/ Oxycontin, patients must be taking a minimum of 20mg/day of oxycodone or its equivalent

    Do not use if opioid requirement is <20mg/day; d/c all other opioids when initiating therapy

    Conversion Formula:
    Mg/Day of Prior Opioid x Conversion Factor = Mg/Day of Oxycontin

    Divide the calculated total daily dose by 2 to get the q12h dose

    Conversion Factors:
    Oxycodone: 1
    Hydrocodone: 0.9
    Hydromorphone: 4 (oral), 20 (parental)
    Morphine: 0.5 (oral), 3 (parental)
    Tramadol: 0.17 (oral), 0.2 (parental)

    Initial: Round down to the nearest Oxycontin dose; if the rounded calculated dose is <20mg, do not initiate
    Titrate: Increase total daily dose by 25% every 1-2 days when clinically indicatedFor patients receiving high-dose parenteral opioids, a more conservative conversion is warranted; for high-dose parenteral morphine, use 1.5 instead of 3 as a multiplication factor

    For patients taking ≥1 opioid, calculate the approx oxycodone dose for each opioid and sum the totals to obtain the approx Oxycontin daily dosage

    For patients on a regimen of fixed-ratio opioid/nonopioid analgesic products, use only the opioid component of these products in the conversion

    If using asymmetric dosing, give higher dose in the am and the lower dose in the pm

    Conversion from Transdermal Fentanyl:
    Initiate treatment 18 hrs following removal of patch; 10mg q12h should be initially substituted for each 25mcg/hr fentanyl transdermal patch


    Concomitant Medications
    If patient is currently on a CNS depressant, initiate Oxycontin at 1/3 to 1/2 the recommended starting dose and monitor

    Hepatic Impairment
    Initiate at 1/3 to 1/2 the recommended starting dose, followed by careful dose titration

    Reduce starting dose to 1/3 to 1/2 the recommended dose in debilitated, opioid-intolerant patients

    Use gradual downward titration


    Oral route

    Do not presoak, lick, or otherwise wet tab prior to placing in mouth.
    Swallow tab whole; do not crush, dissolve, or chew.
    Take 1 tab at a time w/ enough water to ensure complete swallowing.


    Tab, Extended-Release: 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg


    Significant respiratory depression, acute or severe bronchial asthma in unmonitored settings or in the absence of resuscitative equipment, known or suspected paralytic ileus and GI obstruction.


    Reserve use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids for management of chronic pain. 60mg and 80mg tabs, a single dose >40mg, or a total daily dose >80mg are only for use in opioid-tolerant patients. Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients. Consider alternative nonopioid analgesics in patients w/ significant COPD or cor pulmonale, and in patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression. May cause severe hypotension, orthostatic hypotension, and syncope; increased risk in patients whose ability to maintain BP has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressants. Avoid w/ circulatory shock. Monitor patients who may be susceptible to intracranial effects of carbon dioxide retention for signs of sedation and respiratory depression when initiating therapy. Therapy may obscure clinical course in patient w/ head injury. Avoid w/ impaired consciousness or coma. Difficulty in swallowing tab, intestinal obstruction, and exacerbation of diverticulitis reported; consider alternative analgesic in patients who have difficulty swallowing or have underlying GI disorders that may predispose them to obstruction. May cause spasm of sphincter of Oddi and increase in serum amylase; monitor patients w/ biliary tract disease. May aggravate convulsions and induce/aggravate seizures. May impair mental or physical abilities. Urine drug test may not detect oxycodone reliably. Not recommended for use immediately prior to labor.


    Respiratory depression, constipation, N/V, somnolence, dizziness, pruritus, headache, dry mouth, asthenia, sweating, apnea, respiratory arrest, circulatory depression, hypotension.


    See Boxed Warning. Respiratory depression, hypotension, and profound sedation or coma may occur w/ CNS depressants (eg, sedatives, anxiolytics, neuroleptics); if coadministration is required, consider dose reduction of one or both agents. Monitor use in elderly, cachectic, and debilitated patients when coadministered w/ other drugs that depress respiration. May enhance neuromuscular blocking action of true skeletal muscle relaxants and increase respiratory depression. CYP3A4 inhibitors (eg, erythromycin, ketoconazole, ritonavir) may increase levels of oxycodone and prolong opioid effects; these effects could be more pronounced w/ concomitant use of CYP2D6 and 3A4 inhibitors. CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin) may decrease levels and cause lack of efficacy, or development of abstinence syndrome. If coadministration is necessary, use w/ caution when initiating oxycodone treatment in patients currently taking or discontinuing CYP3A4 inhibitors/inducers. Mixed agonist/antagonists (eg, pentazocine, nalbuphine, butorphanol) or partial agonists (buprenorphine) may reduce analgesic effect or precipitate withdrawal symptoms; avoid coadministration. May reduce efficacy of diuretics and lead to acute urinary retention. Anticholinergics or other medications w/ anticholinergic activity may increase risk of urinary retention and/or severe constipation and lead to paralytic ileus.


    Pregnancy: Category C.
    Lactation: Not for use in nursing.


    Full opioid agonist; not established. Specific CNS opioid receptors have been identified throughout the brain and spinal cord and are thought to play a role in analgesic effect.


    Absorption: Oral bioavailability (60-87%). Administration of variable doses resulted in different parameters. Distribution: Vd=2.6L/kg (IV); plasma protein binding (45%); crosses placenta; found in breast milk. Metabolism: Extensive; via CYP3A mediated N-demethylation to noroxycodone and CYP2D6 mediated O-demethylation to oxymorphone; noroxycodone and noroxymorphone (major metabolites). Elimination: Urine; T1/2=4.5 hrs.


    Assess for abuse/addiction risk, pain intensity, prior opioid therapy, opioid tolerance, respiratory depression, drug hypersensitivity, pregnancy/nursing status, possible drug interactions, or any other conditions where treatment is contraindicated or cautioned.


    Monitor for respiratory depression (especially w/in first 24-72 hrs of initiation), hypotension, seizures/convulsions, and other adverse reactions. Monitor BP and serum amylase levels. Routinely monitor for signs of misuse, abuse, and addiction. Periodically reassess the continued need for therapy.


    Inform that use of drug can result in addiction, abuse, and misuse; instruct not to share w/ others and to take steps to protect from theft or misuse. Inform patients about risk of respiratory depression. Advise to store securely and dispose unused tabs by flushing down the toilet. Inform female patients of reproductive potential that prolonged use during pregnancy may result in neonatal opioid withdrawal syndrome and instruct to inform physician if pregnant or planning to become pregnant. Inform that potentially serious additive effects may occur when used w/ CNS depressants, and not to use such drugs unless supervised by healthcare provider. Instruct about proper administration instructions. Inform that drug may cause orthostatic hypotension, syncope, or may impair the ability to perform potentially hazardous activities; advise to not perform such tasks until they know how they will react to medication. Advise of potential for severe constipation, including management instructions. Advise how to recognize anaphylaxis and when to seek medical attention. Advise caregivers to strictly adhere to dosing when giving to pediatric patients.


    25°C (77°F); excursions permitted to 15-30°C (59-86°F).